Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Teresa E Pick

Daniel J Poon

Paul A Renhowe

Cynthia Shafer

Christopher McBride

Barry Haskell Levine

Savithri Ramurthy

Sharadha Subramanian

Paul Andrew Barsanti

Darrin Stuart

Payman Amiri

Jeffrey H Dove

Mina E Aikawa

Mark Knapp

Matthew T Burger

Keith Bruce Pfister

Aaron Matthew Smith

Sabina Pecchi

Allan S Wagman

Simon C Ng

Zhi-Jie Ni

Wendy Fantl

Marion Wiesmann

Yanchen Zhang

Joelle Verhagen

Sarah Bartulis

Charles Voliva

Thomas Hendrickson

Edwin Iwanowicz

Alicia Louie

Kelly Frazier

David Andrew Siesel

Yasheen Zhou

Xiaodong Lin

Yi Xia

Timothy D Machajewski

Abran Q Costales

David M Ryckman

Alice C Rico

Kris Mendenhall

Nathan Brammeier

Gordana Babic Atallah

Maureen McKenna

William R Antonios-McCrea

Hanne Merritt

Danlin Gu

Kristin Brinner

Zhenhai Gao

X Michael Wang

Brandon M Doughan

Jonathan P Van Dyck

Gordana Ataliah

Brian Diaz

Tyson Swiftney

Brady S Stillwell

Bridget R Miller

Martin Dimitroff

Xiaohua Xin

Xiahua Xin

Hanne Meritt

Aaron Smith

David Ryckman

David A Siesel

New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

Substituted benzimidazoles and methods of their use

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. 

Pyrimidine derivatives used as PI-3 kinase inhibitors

Pyrimidine derivatives used as PI-3-kinase inhibitors

Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R, R, R, R, a, b, and c are defined herein 

Substituted benzimidazoles and methods of preparation

Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.

2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones

Growing community of inventors

Danville, CA, United States of America

Teresa E Pick